Plain-English translation of NCT07053917 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Stroke research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial at Johns Hopkins University testing whether psilocybin can help people recover from stroke. Researchers believe this medication may help 'reopen' a window in the brain that allows it to learn and form new memories—similar to how a younger brain learns more easily. The hope is that by reopening this window during rehabilitation, stroke survivors could recover more function.
Stroke is the leading cause of disability in adults, and most people who have a stroke experience lasting problems with movement, speech, or thinking. The brain's ability to heal and relearn after stroke is limited by a critical window that closes over time. This trial is testing whether this medication can reopen that window so rehabilitation becomes more effective.
You likely qualify if…
You likely don't qualify if…
You would receive one or two doses of psilocybin during a supervised visit at Johns Hopkins. The research team will monitor you closely during and after the medication takes effect. You must arrange transportation home (you cannot drive yourself), follow strict guidelines about food and medications before the visit, and agree to stay in contact with the research team for the duration of the study. You will also need to attend follow-up sessions and allow the study team to record your visits.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States